Humana Inc. (HUM)
| Market Cap | 45.64B +62.1% |
| Revenue (ttm) | 154.19B +22.0% |
| Net Income | 1.25B -3.5% |
| EPS | 10.28 -3.7% |
| Shares Out | 120.10M |
| PE Ratio | 36.96 |
| Forward PE | 21.76 |
| Dividend | $3.54 (0.93%) |
| Ex-Dividend Date | Dec 24, 2026 |
| Volume | 1,935,514 |
| Open | 392.72 |
| Previous Close | 385.78 |
| Day's Range | 373.17 - 393.45 |
| 52-Week Range | 163.11 - 462.87 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 510.83 (+34.43%) |
| Earnings Date | Nov 6, 2026 |
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for HUM stock is "Buy." The 12-month stock price target is $510.83, which is an increase of 34.43% from the latest price.
News
UnitedHealth falls another 5.6%, down 15% in two days, as Medicare expansion plans add to audit worries
UnitedHealth fell 5.6% on Thursday and has lost 15% since Tuesday's close. Democratic plans to lower the Medicare eligibility age added to worries about a proposed CMS audit rule.
Humana Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Humana (HUM)
Selling your HUM shares after the November 18 Medicare Advantage selloff does not necessarily end your rights. SueWallSt notifies investors of a pending investigation into whether Humana adequately di...
Humana price target raised to $475 from $370 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Humana (HUM) to $475 from $370 and keeps an Equal Weight rating on the shares. Humana’s benefit discipline and…
UnitedHealth falls 10% and Humana drops 13% as CMS proposes wider Medicare Advantage audits
UnitedHealth fell 10.2% and Humana lost 13% on Wednesday. A proposed CMS rule would extrapolate Medicare Advantage audit findings starting with 2018 payments.
CMS proposal negative for Humana and UnitedHealth, says Mizuho
Mizuho analyst Ann Hynes says the Centers for Medicare and Medicaid Services proposed its “Comprehensive Regulations to Uncover Suspicious Healthcare” rule, which would increase Medicare Advantage ove...
Humana Foundation Marks 45 Years With Nearly $14 Million in Grants to Expand Healthy Food Access and Help Seniors Feel More Connected
LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM), today announced $13.93 million in fall 2026 grants advancing nutrition security, emotional he...
Humana announces launch of national Gold Card program on December 1
Humana (HUM) announced the launch of its national Gold Card program on December 1. “Our goal is straightforward: when prior authorization is necessary, it should be fast, simple and largely…
Humana to Launch National Gold Card Program to Reduce Prior Authorization Requirements
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced the launch of its national Gold Card program on December 1, a key milestone in the company's ongoing public commitment to redu...
Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the expiration and final results of its previously announced cash tender offers (collectively, the ...
Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connect...
Monday's First Moves: GTA VI Presales Top $1B, TSN Earnings, HUM Upgrade
Grand Theft Auto 6 presales have officially topped $1 billion in what is poised to be the biggest video game debut ever. Diane King Hall talks about what the massive launch means for Take-Two Interact...
Humana upgraded to Outperform at RBC Capital on earnings potential
As previously reported, RBC Capital upgraded Humana (HUM) to Outperform from Sector Perform with a price target of $563, up from $415. The company’s “impressive” Stars turnaround, alongside discipline...
Humana upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Humana (HUM) to Outperform from Sector Perform with a price target of $563, up from $415.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana price target raised to $602 from $502 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Humana (HUM) to $602 from $502 and keeps an Overweight rating on the shares after the company beat Q3…
Humana price target raised to $430 from $370 at TD Cowen
TD Cowen raised the firm’s price target on Humana (HUM) to $430 from $370 and keeps a Hold rating on the shares. The firm updated its model following Q3 results…
Humana price target raised to $530 from $495 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Humana (HUM) to $530 from $495 and keeps an Outperform rating on the shares. The main takeover from the company’s…
Humana price target raised to $484 from $393 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Humana (HUM) to $484 from $393 and keeps a Neutral rating on the shares.
New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden
LOUISVILLE, Ky.--(BUSINESS WIRE)--New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden.
Humana price target raised to $516 from $436 at Deutsche Bank
Deutsche Bank analyst George Hill raised the firm’s price target on Humana (HUM) to $516 from $436 and keeps a Buy rating on the shares. The company reported better than…
Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding n...
Humana Earnings Call Transcript: Q3 2026
2026 adjusted EPS guidance rose to at least $9.50, with individual MA margins on track to double excluding the Stars headwind. Strong BY28 Stars results and early AEP indicators support the recovery, while higher 2027 cost trends remain a key consideration.
Humana Earnings release: Q3 2026
Humana released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.

